Phibro Animal Health (NASDAQ:PAHC) CEO Sells $235,429.36 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,752 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $40.93, for a total value of $235,429.36. Following the completion of the transaction, the chief executive officer owned 39,200 shares in the company, valued at $1,604,456. This represents a 12.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total transaction of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.93, for a total transaction of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total transaction of $232,425.60.
• On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.56, for a total transaction of $235,276.80.
• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.47, for a total transaction of $391,380.47.
• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.23, for a total transaction of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87.
• On Friday, November 7th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $42.86, for a total value of $150,867.20.

Phibro Animal Health Price Performance

PAHC stock traded up $0.52 during mid-day trading on Monday, hitting $40.67. 169,789 shares of the stock were exchanged, compared to its average volume of 279,859. The business has a fifty day moving average price of $41.23 and a 200 day moving average price of $34.66. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $46.42. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.14 and a beta of 0.77.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The company had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Wednesday, November 26th. Phibro Animal Health’s payout ratio is presently 28.92%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Bank of America increased their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, August 29th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 8th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. lifted their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Morgan Stanley set a $34.00 target price on Phibro Animal Health in a report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $31.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Phibro Animal Health by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock worth $32,500,000 after buying an additional 6,784 shares during the period. Acadian Asset Management LLC increased its stake in shares of Phibro Animal Health by 0.5% during the first quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock valued at $16,713,000 after buying an additional 4,144 shares during the period. Geode Capital Management LLC raised its holdings in shares of Phibro Animal Health by 1.4% during the second quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock valued at $14,175,000 after acquiring an additional 7,841 shares in the last quarter. Nuveen LLC purchased a new stake in Phibro Animal Health in the first quarter worth $10,312,000. Finally, Invesco Ltd. boosted its holdings in Phibro Animal Health by 92.3% in the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after acquiring an additional 186,087 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.